Allogene amends certificate to increase authorized shares to 810M

Allogene Therapeutics increased total authorized shares from previous levels to 810 million, comprising 800 million common shares and 10 million preferred shares. The amendment, approved by shareholders and effective June 18, 2026, provides additional capital structure flexibility for future financing or corporate actions.